β1,4-galactosyltransferase III drives retinoblastoma invasion via activation of integrin-FAK axis.

Retinoblastoma (RB) is the most common primary intraocular malignancy in children, and its extraocular extension is closely linked to poor prognosis. However, the molecular drivers underlying local invasion remain incompletely defined. Here, we identify β‑1,4‑galactosyltransferase III (B4GALT3) as a glycosyltransferase selectively upregulated in highly proliferative MKI67⁺ RB subpopulations. B4GALT3 promotes RB cell proliferation, fibronectin adhesion, and invasion by enhancing β1-integrin glycosylation, thereby activating FAK signaling and inducing MMP2 expression to disrupt retinal epithelial barriers. Genetic modulation of B4GALT3 significantly altered both tumor burden and invasive behavior in orthotopic xenograft models. Structure-based virtual screening identified myricoside as a B4GALT3 inhibitor, which suppressed RB malignancy in vitro and in vivo. Overall, our findings uncover a B4GALT3-integrin-FAK axis as a key regulator of RB progression and highlight B4GALT3 inhibition as a promising therapeutic strategy for advanced RB.